Traws Pharma (ONTX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ONTX Stock Forecast


Traws Pharma stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

ONTX Analyst Ratings


Buy

According to 2 Wall Street analysts, Traws Pharma's rating consensus is 'Buy'. The analyst rating breakdown for ONTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Apr 21, 2023H.C. WainwrightBuyUpgrade
May 18, 2021GuggenheimBuyInitialise
Row per page
Go to

Traws Pharma's last stock rating was published by H.C. Wainwright on Apr 21, 2023. The company Upgrade its ONTX rating from "null" to "Buy".

Traws Pharma Financial Forecast


Traws Pharma Revenue Forecast

Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19Mar 19Mar 18Mar 17Mar 16Mar 15Mar 14Oct 13
Revenue-------$56.00K$56.00K--$56.00K$-58.00K--$56.00K$57.00K--$52.00K$30.00K--$68.00K$564.00K$210.00K$1.47M$114.00K$447.00K-
Avg Forecast$2.72M$60.00K$60.00K$60.00K$65.33K$69.25K$69.25K$79.00K$80.00K$73.67K$73.00K$79.00K$59.50K$53.33K$20.00K$60.00K$45.00K$1.39M$173.00K$88.00K$66.50K$803.67K$494.75K$85.00K$647.84K$171.53K$1.03M$121.58K$381.45K$751.52K
High Forecast$2.72M$60.00K$60.00K$60.00K$65.33K$69.38K$69.25K$79.00K$80.00K$73.67K$73.00K$79.00K$59.50K$53.33K$20.00K$60.00K$45.00K$1.39M$173.00K$88.00K$66.50K$803.67K$494.75K$85.00K$777.41K$205.83K$1.24M$145.89K$457.74K$901.82K
Low Forecast$2.72M$60.00K$60.00K$60.00K$65.33K$69.13K$69.25K$79.00K$80.00K$73.67K$73.00K$79.00K$59.50K$53.33K$20.00K$60.00K$45.00K$1.39M$173.00K$88.00K$66.50K$803.67K$494.75K$85.00K$518.27K$137.22K$827.55K$97.26K$305.16K$601.21K
# Analysts111121111111111147443533991381013
Surprise %-------0.71%0.70%--0.71%-0.97%--0.93%1.27%--0.59%0.45%--0.80%0.87%1.22%1.42%0.94%1.17%-

Traws Pharma's average Quarter revenue forecast for Jul 23 based on 1 analysts is $69.25K, with a low forecast of $69.25K, and a high forecast of $69.25K. ONTX's average Quarter revenue forecast represents a 23.66% increase compared to the company's last Quarter revenue of $56.00K (Mar 23).

Traws Pharma EBITDA Forecast

Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19Mar 19Mar 18Mar 17Mar 16Mar 15Mar 14Oct 13
# Analysts111121111111111147443533991381013
EBITDA-------$-6.13M$-5.73M--$-4.13M$-3.76M--$-4.71M$-2.42K--$-5.09M$-5.74M--$-7.59M$-5.07M$-8.32M$-7.22M$-12.27M$-18.54M-
Avg Forecast$-2.72M$-60.00K$-60.00K$-60.00K$-65.33K$-69.25K$-69.25K$-79.00K$-80.00K$-73.67K$-73.00K$-3.90M$-59.50K$-53.33K$-20.00K$-6.28M$-45.00K$-1.39M$-173.00K$-6.41M$-66.50K$-803.67K$-494.75K$-5.68M$-5.76M$-6.45M$-4.60M$-13.44M$-15.21M$-10.28M
High Forecast$-2.72M$-60.00K$-60.00K$-60.00K$-65.33K$-69.13K$-69.25K$-79.00K$-80.00K$-73.67K$-73.00K$-3.12M$-59.50K$-53.33K$-20.00K$-5.03M$-45.00K$-1.39M$-173.00K$-5.13M$-66.50K$-803.67K$-494.75K$-4.54M$-4.61M$-5.16M$-3.68M$-10.75M$-12.17M$-8.23M
Low Forecast$-2.72M$-60.00K$-60.00K$-60.00K$-65.33K$-69.38K$-69.25K$-79.00K$-80.00K$-73.67K$-73.00K$-4.68M$-59.50K$-53.33K$-20.00K$-7.54M$-45.00K$-1.39M$-173.00K$-7.69M$-66.50K$-803.67K$-494.75K$-6.81M$-6.91M$-7.74M$-5.51M$-16.13M$-18.25M$-12.34M
Surprise %-------77.65%71.67%--1.06%63.19%--0.75%0.05%--0.79%86.38%--1.34%0.88%1.29%1.57%0.91%1.22%-

undefined analysts predict ONTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Traws Pharma's previous annual EBITDA (undefined) of $NaN.

Traws Pharma Net Income Forecast

Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19Mar 19Mar 18Mar 17Mar 16Mar 15Mar 14Oct 13
# Analysts111121111111111147443533991381013
Net Income-------$-5.41M$-5.00M--$-4.11M$-3.76M--$-4.71M$-6.43K--$-5.09M$-5.75M--$-7.60M$-5.09M$-8.34M$-7.24M$-12.34M$-18.68M-
Avg Forecast$-5.16M$-5.58M$-5.26M$-4.95M$-5.33M$-6.10M$-6.58M$-6.26M$-5.84M$-4.47M$-4.16M$-3.91M$-5.68M$-6.87M$-6.00M$-6.29M$-10.52M$-10.52M$-9.47M$-6.42M$-22.10M$-221.75M$-277.77M$-5.68M$-5.78M$-6.47M$-4.61M$-13.52M$-15.32M$-10.57M
High Forecast$-5.16M$-5.58M$-5.26M$-4.95M$-5.33M$-6.10M$-6.58M$-6.26M$-5.84M$-4.47M$-4.16M$-3.12M$-5.68M$-6.87M$-6.00M$-5.03M$-10.52M$-10.52M$-9.47M$-5.13M$-22.10M$-221.75M$-277.77M$-4.55M$-4.62M$-5.18M$-3.69M$-10.81M$-12.26M$-8.45M
Low Forecast$-5.16M$-5.58M$-5.26M$-4.95M$-5.33M$-6.10M$-6.58M$-6.26M$-5.84M$-4.47M$-4.16M$-4.69M$-5.68M$-6.87M$-6.00M$-7.54M$-10.52M$-10.52M$-9.47M$-7.70M$-22.10M$-221.75M$-277.77M$-6.82M$-6.94M$-7.76M$-5.53M$-16.22M$-18.39M$-12.68M
Surprise %-------0.86%0.86%--1.05%0.66%--0.75%0.00%--0.79%0.26%--1.34%0.88%1.29%1.57%0.91%1.22%-

Traws Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ONTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Traws Pharma SG&A Forecast

Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19Mar 19Mar 18Mar 17Mar 16Mar 15Mar 14Oct 13
# Analysts111121111111111147443533991381013
SG&A-------$2.11M$2.02M--$2.19M$2.07M--$2.22M$1.78M--$1.81M$1.71M--$3.23M$1.89M$2.12M$3.17M$2.96M$4.93M-
Avg Forecast$86.60M$1.91M$1.91M$1.91M$2.08M$2.20M$2.20M$2.52M$2.55M$2.35M$2.32M$2.52M$1.89M$1.70M$636.74K$1.91M$1.43M$44.37M$5.51M$2.80M$2.12M$25.59M$15.75M$2.71M$20.63M$5.46M$32.93M$3.87M$12.14M$23.93M
High Forecast$86.60M$1.91M$1.91M$1.91M$2.08M$2.21M$2.20M$2.52M$2.55M$2.35M$2.32M$2.52M$1.89M$1.70M$636.74K$1.91M$1.43M$44.37M$5.51M$2.80M$2.12M$25.59M$15.75M$2.71M$24.75M$6.55M$39.52M$4.64M$14.57M$28.71M
Low Forecast$86.60M$1.91M$1.91M$1.91M$2.08M$2.20M$2.20M$2.52M$2.55M$2.35M$2.32M$2.52M$1.89M$1.70M$636.74K$1.91M$1.43M$44.37M$5.51M$2.80M$2.12M$25.59M$15.75M$2.71M$16.50M$4.37M$26.35M$3.10M$9.72M$19.14M
Surprise %-------0.84%0.79%--0.87%1.09%--1.16%1.24%--0.64%0.81%--1.20%0.09%0.39%0.10%0.77%0.41%-

Traws Pharma's average Quarter SG&A projection for Jul 23 is $2.20M, based on 1 Wall Street analysts, with a range of $2.20M to $2.20M. The forecast indicates a 4.34% rise compared to ONTX last annual SG&A of $2.11M (Mar 23).

Traws Pharma EPS Forecast

Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19Mar 19Mar 18Mar 17Mar 16Mar 15Mar 14Oct 13
# Analysts111121111111111147443533991381013
EPS-------$-0.26$-0.24--$-0.20$-0.24--$-0.30$-0.00--$-0.45$-14.04--$-19.35$-76.50$-276.75$-607.49$-1.28K$-1.96K-
Avg Forecast$-0.24$-0.27$-0.25$-0.23$-0.25$-0.29$-0.31$-0.30$-0.28$-0.21$-0.20$-0.19$-0.27$-0.33$-0.28$-0.45$-0.50$-0.50$-0.45$-0.82$-1.05$-10.54$-13.20$-15.53$-6.70$-11.69$-1.21$-6.90$-90.74$-50.40
High Forecast$-0.24$-0.27$-0.25$-0.23$-0.25$-0.29$-0.31$-0.30$-0.28$-0.21$-0.20$-0.19$-0.27$-0.33$-0.28$-0.45$-0.50$-0.50$-0.45$-0.82$-1.05$-10.54$-13.20$-15.53$-5.36$-9.35$-0.97$-5.52$-72.59$-40.32
Low Forecast$-0.24$-0.27$-0.25$-0.23$-0.25$-0.29$-0.31$-0.30$-0.28$-0.21$-0.20$-0.19$-0.27$-0.33$-0.28$-0.45$-0.50$-0.50$-0.45$-0.82$-1.05$-10.54$-13.20$-15.53$-8.04$-14.03$-1.45$-8.28$-108.89$-60.48
Surprise %-------0.87%0.86%--1.07%0.89%--0.67%0.00%--0.55%13.37%--1.25%11.42%23.67%502.06%185.87%21.57%-

According to undefined Wall Street analysts, Traws Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ONTX previous annual EPS of $NaN (undefined).

Traws Pharma Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VBIVVBI Vaccines--7042.86%Strong Buy
ONTXTraws Pharma--600.00%Buy
OCGNOcugen--455.56%Buy
VXRTVaxart--233.33%Hold
GOVXGeoVax Labs--196.30%Buy
PALIPalisade Bio---38.52%Buy

ONTX Forecast FAQ


Is Traws Pharma a good buy?

Yes, according to 2 Wall Street analysts, Traws Pharma (ONTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ONTX's total ratings.

What are Traws Pharma's analysts' financial forecasts?

ONTX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.9M (high $2.9M, low $2.9M), average EBITDA is $-2.9M (high $-2.9M, low $-2.9M), average net income is $-20.938M (high $-20.938M, low $-20.938M), average SG&A $92.33M (high $92.33M, low $92.33M), and average EPS is $-0.995 (high $-0.995, low $-0.995).

Did the ONTX's actual financial results beat the analysts' financial forecasts?

Based on Traws Pharma's last annual report (Dec 2023), the company's revenue was $226B, beating the average analysts forecast of $282.83K by 79905710.14%. Apple's EBITDA was $-20.298T, beating the average prediction of $-283K by 7176673060.49%. The company's net income was $-18.948T, beating the average estimation of $-24.27M by 78071429.39%. Apple's SG&A was $9.09T, beating the average forecast of $9M by 100993522.21%. Lastly, the company's EPS was $-0.9, missing the average prediction of $-1.153 by -21.97%. In terms of the last quarterly report (Mar 2023), Traws Pharma's revenue was $56K, missing the average analysts' forecast of $79K by -29.11%. The company's EBITDA was $-6.134M, beating the average prediction of $-79K by 7664.56%. Traws Pharma's net income was $-5.413M, missing the average estimation of $-6.26M by -13.54%. The company's SG&A was $2.11M, missing the average forecast of $2.52M by -15.99%. Lastly, the company's EPS was $-0.26, missing the average prediction of $-0.297 by -12.61%